ArticleAdvanced materials technologies2025
Automated, Deep Learning-Enabled Immunoassay Microfluidic Cartridge for Viral Pathogen Detection.
Article in Advanced materials technologies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AI-Enabled Microfluidics for Respiratory Pathogen Detection.Sensors (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Enzyme-linked immunosorbent assays (ELISA) are recognized for their accuracy and versatility in disease diagnostics. However, conventional ELISA protocols rely on laboratory equipment, trained personnel, and established infrastructure, restricting their use to complex clinical environments, making them impractical for at-home diagnostics. Here, VISTA, a disposable, electricity-free microfluidic chip designed for immunoassay-based point-of-care diagnostic applications is reported. VISTA enables a bubbling immunoassay-based assay to be completed, sample-to-result, in under 45 min in non-laboratory settings. Using pressure-driven microfluidics, the device manipulates antibody-conjugated magnetic beads and platinum nanoparticles to execute a streamlined semiautomated immunoassay process with minimal user input. VISTA consolidates all steps, including sample processing and reagent addition, into a single, low-cost cartridge with user-friendly features to ensure proper operation. It pairs with an AI-enabled smartphone application, utilizing an adversarial neural network, that automatically interprets assay results from a smartphone image, eliminating the need for specialized expertise. The device's capability is demonstrated through the bubbling immunoassay to detect SARS-CoV-2 N antigen and HCV core antigen directly from 52 patient samples. VISTA's sensitivity is on par with lab-based ELISAs and surpasses conventional point-of-care technologies, detecting viral loads less than 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.